SCOTLAND: It was announced last week (9th February) that sotatercept, the ‘first in class’ pulmonary arterial hypertension treatment, will not be commissioned for use by NHS Scotland at this stage. Our fellow patient advocates at the PHA UK note that whilst this is disappointing news initial refusal is common for new and specialised drugs, and sotatercept is an expensive therapy – considerably higher than every other treatment that is currently available. It is likely a decision will be reconsidered following further submissions by MSD, the pharmaceutical company behind the drug.
ENGLAND: The drug was refused for use by NHS England in August last year, and a second appraisal meeting was held in December 2025.PHA UK confirms that the sotatercept review process in England has been paused whilst commercial discussions take place with the drug manufacturers.